TL;DR:

I’m four days into a transformative research visit at the Slavcev Lab, exploring the potential of phage display systems for vaccine design, starting with typhoid. This experience has highlighted the power of phage biology in addressing global health challenges and inspired a renewed focus on advancing phage therapy solutions at the Center for Phage Biology and Therapeutics in Jos, Nigeria. Equipped with foundational resources, we aim to build a robust research team, mentor the next generation of innovators, and establish a biotech company to deliver phage-based therapeutics and vaccines to underserved populations. Excited to connect with global health professionals and researchers to drive impactful solutions together!

Just four days

It’s been just four days since I joined the Slavcev Lab, and I am already captivated by the transformative potential of phage display research. This visit represents a pivotal step in my quest to design innovative vaccines, starting with typhoid—a disease that continues to threaten vulnerable populations worldwide.

My focus here is to harness phage display systems as a platform for vaccine development, leveraging precision and ingenuity to create solutions that address some of the most persistent global health challenges. These early days have offered invaluable insights, from hands-on experimentation with phage display platforms to thought-provoking discussions on molecular design strategies. The dynamic culture of collaboration and innovation in the Slavcev Lab has been truly inspiring, and I’m eager to bring these experiences back to Nigeria.

At the Center for Phage Biology and Therapeutics in Jos, we are laying the foundation for impactful phage research with the available tools. Our centre is focused on developing phage therapy solutions for antibiotic-resistant infections while also exploring the frontiers of phage-based vaccine design. This visit has reaffirmed that we can pursue ambitious research goals, build a strong interdisciplinary team of students and researchers, and position the centre as a hub for phage biotechnology in Africa.

With funding support from Emergent Ventures, we set up a phage-based lab, Centre for Phage Biology and Therapeutics, Jos. The lab is fairly new and modestly equipped.

Our vision extends beyond the lab. We aim to cultivate talent, foster cutting-edge research, and eventually establish a biotech company that delivers practical phage-based therapeutics and vaccines to address unmet global health needs. This alignment of science, innovation, and public health impact drives me daily.

Conclusion

I am profoundly grateful for the opportunity to learn from the exceptional team at the Slavcev Lab. This experience strengthens my commitment to leveraging phage biology as a tool for equitable health solutions. This is especially important for my country, where most of our research is consumer-focused. We need homegrown solutions to local and global health problems.
For global health professionals, researchers, and those invested in the fight against infectious diseases, I’d love to exchange ideas on how to accelerate the development of these life-saving technologies collaboratively. Together, we can shape a healthier future for all.